Table 3.
Comparison of clinical characteristics between cases that remained with ocular myasthenia gravis with secondary generalized myasthenia gravis.
| SGMG | OMG-R | χ2/Z value | P-value | |
|---|---|---|---|---|
| Gender | ||||
| Male | 5 (26) | 64 (45) | 2.407 | 0.121 |
| Female | 14 (74) | 78 (55) | ||
| Age of onset (mean, months) | 82.7 | 81.2 | −0.138 | 0.891 |
| Follow-up duration (mean, months) | 81.5 | 88.8 | −0.671 | 0.502 |
| Proceeding events | ||||
| Yes | 3 (16) | 24 (18) | 1.000 | |
| No | 16 (84) | 110 (82) | ||
| Onset manifestation | ||||
| Ptosis | 17 (89) | 129 (95) | 0.897 | 0.304 |
| Ptosis and other ocular manifestation | 2 (11) | 7 (5) | ||
| AChR-Ab (positive) | 9 (50) | 35 (38) | 0.344 | |
| Abnormal RNS | 3 (60) | 17 (59) | 0.646 | |
| Thyroid-related abnormalities | 4 (24) | 17 (13) | 0.276 | |
SGMG, secondary generalized myasthenia gravis; OMG-R, remained ocular myasthenia gravis at the end of follow-up; AChR-Ab, antibody against acetylcholine receptors; RNS, abnormal neurophysiology.